ReviewMicrobial biotechnology2025
Engineered Bacteria for Disease Diagnosis and Treatment Using Synthetic Biology.
Review in Microbial biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Engineered bacterial therapeutics from synthetic biology to clinical translation: A multi-database scientometric analysis, 2000-2026.Human vaccines & immunotherapeutics · 2026Review
- Engineered bacteria in disease diagnosis and therapy: A synthetic biology perspective.Synthetic and systems biotechnology · 2026Review
- The Gut Microbiome in Early Ontogeny: Implications for Brain and Immune System Development.Journal of developmental biology · 2026Review
- Butyrate-Producing Bacteria in Intestinal Disease Therapy: Potential and Challenges.Biotechnology journal · 2026Review
- Expanding salivary biomarker detection by creating a synthetic neuraminic acid sensor via chimeragenesis.Applied and environmental microbiology · 2026Article
- Genetically Modified Lactic Acid Bacteria in the EU Food Chain: Applications, Benefits, and Risk Assessment.International journal of molecular sciences · 2026Review
- Review
- A Manifesto for Universal Healthcare: Reconstituting Primary Care Through Digital Innovation, Microbial Technologies and Empowered Citizenship.Microbial biotechnology · 2026Article
- Advance Microbiota Transplantation: A Novel Addition-Subtraction Paradigm for Optimising Faecal Microbiota Transplantation.Microbial biotechnology · 2026Review
- Review
- Probiotics: multifunctional microorganisms for human health and biotechnological applications.Frontiers in microbiology · 2026Review
- Emerging Nanoplatforms are Effective Against Tumor Hypoxia.International journal of nanomedicine · 2026Review
- Synthetic biology and genome engineering in support of human, agricultural, and environmental security.Frontiers in bioengineering and biotechnology · 2026Article
- Microbiome-Driven Mechanisms in Breast Cancer: Emerging Evidence From Gut Microbial Signatures to Therapeutic Response.BioMed research international · 2026Review
- Microbial allies in skin trauma recovery: from immune modulation to engineered probiotic therapeutics.Burns & trauma · 2026Review
- Engineering bifidobacteria to deliver CRISPR antimicrobials targeting oncogenicAnnals of medicine and surgery (2012) · 2026Article
- Microbiota-derived short-chain fatty acids in hematopoietic stem cell transplantation: immunomodulation at the host-microbiota interface.Frontiers in microbiology · 2026Review
- Novel Microbiome-Driven Approaches to Counteract Chemotherapy-Induced Mucositis in Breast Cancer Patients.Breast cancer (Dove Medical Press) · 2026Review
- Engineered Clostridium butyricum: a promising application of synthetic biology in comprehensive health.Microbial cell factories · 2025Review
- Biocomputing networks for distributed monitoring of foodborne pathogen outbreaks using engineered bacterial sensors.Annals of medicine and surgery (2012) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Using synthetic biology techniques, bacteria have been engineered to serve as microrobots for diagnosing diseases and delivering treatments. These engineered bacteria can be used individually or in combination as microbial consortia. The components within these consortia complement each other, enhancing diagnostic accuracy and providing synergistic effects that improve treatment efficacy. The application of microbial therapies in cancer, intestinal diseases, and metabolic disorders underscores their significant potential. The impact of these therapies on the host's native microbiota is crucial, as engineered microbes can modulate and interact with the host's microbial environment, influencing treatment outcomes and overall health. Despite numerous advancements, challenges remain. These include ensuring the long-term survival and safety of bacteria, developing new chassis microbes and gene editing techniques for non-model strains, minimising potential toxicity, and understanding bacterial interactions with the host microbiota. This mini-review examines the current state of engineered bacteria and microbial consortia in disease diagnosis and treatment, highlighting advancements, challenges, and future directions in this promising field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.